regorafenib
Showing 26 - 50 of 138
Colorectal Cancer Metastatic Trial in France (Regorafenib)
Recruiting
- Colorectal Cancer Metastatic
- Regorafenib
-
Brest, France
- +11 more
Dec 7, 2022
Metastatic Pancreatic Adenocarcinoma Trial in Cleveland (Regorafenib, Gemcitabine Hydrochloride)
Terminated
- Metastatic Pancreatic Adenocarcinoma
- Regorafenib
- Gemcitabine Hydrochloride
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jun 1, 2022
Colorectal Cancer, Colorectal Cancer Metastatic Trial in United States (Pembrolizumab, Regorafenib)
Active, not recruiting
- Colorectal Cancer
- Colorectal Cancer Metastatic
- Pembrolizumab
- Regorafenib
-
Duarte, California
- +3 more
Aug 5, 2022
Pancreas Cancer, Ovarian Cancer, Melanoma Trial in Rozzano (Regorafenib)
Completed
- Pancreas Cancer
- +6 more
- Regorafenib
-
Rozzano, Milan, ItalyIstituto Clinico Humanitas
Sep 9, 2022
Colorectal Cancer Trial in Philadelphia (Regorafenib, 5-FU, Leucovorin)
Terminated
- Colorectal Cancer
- Regorafenib
- +2 more
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Jan 10, 2022
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Kashiwa (Regorafenib,
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- Regorafenib
- +3 more
-
Kashiwa, Chiba, JapanNational Cancer Center Hospital East
May 23, 2022
Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Regorafenib + sintilimab, Regorafenib)
Recruiting
- Hepatocellular Carcinoma Non-resectable
- Regorafenib + sintilimab
- Regorafenib
-
Guangzhou, Guangdong, Chinathe Second Affiliated Hospital of Guangzhou Medical University
Feb 10, 2022
Metastatic Colorectal Cancer Trial in France (other, procedure, drug)
Not yet recruiting
- Metastatic Colorectal Cancer
- quality of life questionnaires
- +6 more
-
Besançon, France
- +6 more
Jul 15, 2022
Ovarian Cancer, Serous Ovarian Cancer Trial in Pittsburgh (Regorafenib, Fulvestrant)
Not yet recruiting
- Ovarian Cancer
- Serous Ovarian Cancer
- Regorafenib
- Fulvestrant
-
Pittsburgh, PennsylvaniaUniversity of Pittsburgh Cancer Institute
Apr 17, 2022
Esophagogastric Cancer, HER2-Negative Trial in United States (regorafenib, nivolumab, FOLFOX chemo with oxaliplatin)
Active, not recruiting
- Esophagogastric Cancer
- HER2-Negative
- regorafenib
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Nov 23, 2022
Adenoid Cystic Carcinoma Trial in United States (Regorafenib)
Active, not recruiting
- Adenoid Cystic Carcinoma
- Regorafenib
-
Basking Ridge, New Jersey
- +4 more
Apr 26, 2022
Thyroid Cancer Trial in New Haven, Boston (Regorafenib)
Recruiting
- Thyroid Cancer
- Regorafenib
-
New Haven, Connecticut
- +1 more
Feb 18, 2022
Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC
Not yet recruiting
- Stage IB Hepatocellular Carcinoma AJCC v8
- +2 more
- Durvalumab
- Regorafenib
-
Gainesville, Florida
- +3 more
Jun 15, 2022
Advanced Biliary Tract Cancer Trial in United States (Durvalumab, Regorafenib)
Recruiting
- Advanced Biliary Tract Cancer
- Durvalumab
- Regorafenib
-
Overland Park, Kansas
- +4 more
May 17, 2022
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma Trial in United States
Completed
- Adult Angiosarcoma
- +3 more
- regorafenib
-
Santa Monica, California
- +6 more
Mar 29, 2022
Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma Trial in United States (Regorafenib, Placebo)
Completed
- Liposarcoma
- +4 more
- Regorafenib
- Placebo
-
Duarte, California
- +17 more
Oct 25, 2022
Glioblastoma Multiforme Trial in Italy (Regorafenib, Lomustine)
Active, not recruiting
- Glioblastoma Multiforme
- Regorafenib
- Lomustine
-
Castellana Grotte, BA, Italy
- +9 more
Mar 31, 2022
Rectal Cancer Trial in Switzerland (drug, radiation, procedure)
Terminated
- Rectal Cancer
- Regorafenib
- +3 more
-
Basel, Switzerland
- +6 more
Jan 14, 2022
KRAS Gene Mutation, Metastatic Malignant Tumor in the Brain, Recurrent Non-Small Cell Lung Carcinoma Trial in Palo Alto
Active, not recruiting
- KRAS Gene Mutation
- +3 more
- Methotrexate
- +2 more
-
Palo Alto, CaliforniaStanford University School of Medicine
Feb 9, 2022
Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)
Not yet recruiting
- Hepatocellular Carcinoma
- iNKT Cells
- +2 more
-
Beijing, Beijing, ChinaBeijing Youan Hospital,Capital Medical University
Jul 24, 2023
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1
Not yet recruiting
- HCC
- +3 more
- Regorafenib
- cTACE/DEB-TACE-HAIC
- (no location specified)
Aug 28, 2021